Imbruvica/Venclyxto tops Gazyva plus chemo in first-line CLL/SLL

Johnson & Johnson’s BTK inhibitor Imbruvica plus AbbVie and Roche’s Vencylxto demonstrated superiority over Gazyva plus chemotherapy in a new Phase III study. In elderly and unfit patients with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), fixed-duration Imbruvica (ibrutinib) plus Venclyxto (venetoclax) had superior progression free survival (PFS) compared to Gazyva […]